Evidence map›Paper›PMID 33135682›Full record

ArticleActa crystallographica. Section D, Structural biology2020

Flipping the substrate preference of Hazara virus ovarian tumour domain protease through structure-based mutagenesis.

John V Dzimianski, Savannah L Mace, Isabelle L Williams, Brendan T Freitas, Scott D Pegan

Open access · greenAbstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

John V DzimianskiPharmaceutical and Biomedical Sciences, University of Georgia, 240 West Green Street, Athens, GA 30602, USA.ORCID 0000-0002-2447-146X
Savannah L MacePharmaceutical and Biomedical Sciences, University of Georgia, 240 West Green Street, Athens, GA 30602, USA.
Isabelle L WilliamsPharmaceutical and Biomedical Sciences, University of Georgia, 240 West Green Street, Athens, GA 30602, USA.
Brendan T FreitasPharmaceutical and Biomedical Sciences, University of Georgia, 240 West Green Street, Athens, GA 30602, USA.ORCID 0000-0001-5847-5904
Scott D PeganPharmaceutical and Biomedical Sciences, University of Georgia, 240 West Green Street, Athens, GA 30602, USA.ORCID 0000-0002-2958-5319
University of Georgia · US

Funding

Origin of the innate immunity suppression caused by nairovirus' protease activityR01AI151006 · NIAID · UNIVERSITY OF GEORGIA · PI PEGAN, SCOTT DUSAN · 2020 to 2024
$2.1M
Origin of the innate immunity suppression caused by nairovirus' protease activityR01AI109008 · NIAID · UNIVERSITY OF GEORGIA · PI PEGAN, SCOTT DUSAN · 2014 to 2018
$1.6M
National Institutes of Health, National Institute of Allergy and Infectious Diseases AI151006NIAID NIH HHS R01 AI109008NIAID NIH HHS R01 AI151006
6 · The paper itself

Abstract

Nairoviruses are arthropod-borne viruses with a nearly global geographical distribution. Several are known causative agents of human disease, including Crimean-Congo hemorrhagic fever virus (CCHFV), which has a case fatality rate that can exceed 30%. Nairoviruses encode an ovarian tumour domain protease (OTU) that can suppress the innate immune response by reversing post-translational modifications by ubiquitin (Ub) and/or interferon-stimulated gene product 15 (ISG15). As a result, the OTU has been identified as a potential target for the development of CCHFV therapeutics. Despite sharing the same general fold, nairoviral OTUs show structural and enzymatic diversity. The CCHFV OTU, for example, possesses activity towards both Ub and ISG15, while the Hazara virus (HAZV) OTU interacts exclusively with Ub. Virology studies focused on the OTU have mostly been restricted to CCHFV, which requires BSL-4 containment facilities. Although HAZV has been proposed as a BSL-2 alternative, differences in the engagement of substrates by CCHFV and HAZV OTUs may present complicating factors when trying to model one using the other. To understand the molecular underpinnings of the differences in activity, a 2.78 Å resolution crystal structure of HAZV OTU bound to Ub was solved. Using structure-guided site-directed mutagenesis, HAZV OTUs were engineered with altered or eliminated deubiquitinase activity, including one with an exclusive activity for ISG15. Additionally, analysis of the structure yielded insights into the difference in inhibition observed between CCHFV and HAZV OTUs with a Ub-based inhibitor. These new insights present opportunities to utilize HAZV as a model system to better understand the role of the OTU in the context of infection.

Indexed as

Peptide HydrolasesUbiquitinViral ProteinsModels, MolecularNairovirusProtein BindingProtein DomainsPeptide HydrolasesUbiquitinViral ProteinsCrimean–Congo hemorrhagic feverISG15nairovirusesovarian tumour domainubiquitin

Identifiers

PMID33135682
PMCPMC7604911
OpenAlexW3094027933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.